Scotiabank lowered the firm’s price target on Rocket Pharmaceuticals (RCKT) to $19 from $51 and keeps an Outperform rating on the shares. Shares of the stock are under pressure after the phase 2 trial of RP-A501 in Danon disease was placed on a clinical hold by the FDA, the analyst tells investors. The firm recognizes this is a major setback for Rocket, but still sees a chance for this safety issue to be resolved.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Broadcom, Arista Networks initiated: Wall Street’s top analyst calls
- Goldman downgrades Rocket to Sell on ‘surprising and concerning’ update
- Rocket Pharmaceuticals downgraded to Sell from Neutral at Goldman Sachs
- Rocket Pharmaceuticals: Buy Rating Affirmed Amid Strategic Adjustments and Financial Resilience
- Rocket Pharmaceuticals price target lowered to $17 from $46 at Chardan
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue